Skip to search formSkip to main contentSkip to account menu

MVT-5873

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Anti-CA19-9 Monoclonal Antibody 5B1

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract A062: Using CA19-9 as a translational biomarker for sLea targeted agents MVT-5873 and MVT-1075 in cancer
Background: Sialyl Lewis A (sLea) modification occurs on transmembrane and secreted proteins in pancreatic ductal adenocarcinoma… 
2016
2016
Abstract A73: Antitumor activity of MVT-5873, a monoclonal antibody targeting sialyl Lewisa, alone and in combination with gemcitabine/nab-paclitaxel in a BxPC3 human pancreatic cancer xenograft…
Introduction: MVT-5873 (HuMab-5B1) is a fully human monoclonal antibody that specifically targets the sialyl Lewis A (sLea… 
2016
2016
Abstract CT026: Phase I trial of HuMab-5B1 (MVT-5873), a novel monoclonal antibody targeting sLea, in patients with advanced pancreatic cancer and other CA19-9 positive malignancies
MVT-5873 (HuMab-5B1) is a fully human, IgG1 antibody targeting sialyl Lewis A (sLea), an epitope present on CA19-9. MVT-5873 was… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)